First-Line Treatment for Alopecia Areata
Alopecia areata (AA) presents as focal, non-scarring hair loss. A consensus of specialists supports a defined first-line pharmacological approach — applicable regardless of patient age or disease severity — with a measurable 12-week outcome target.
Treatment approach
The first-line strategy centres on a topical corticosteroid-based intervention applied directly to the affected area. The complete potency selection criteria, application technique, and management of refractory cases are detailed in the full protocol.
Clinical target
The primary measurable outcome at 12 weeks:
≥ 25% hair regeneration of the affected scalp area
References
DOI: 10.14924/dermatol.134.2491
- According to a consensus study by 50 specialists in AA treatment in the world, which was reported in 2020, topical corticosteroid application is first-line treatment regardless of age or severity.
- It is recommended regardless of severity, especially for children aged ≤ 12 years.
- There is a highly reliable report from a RCT regarding the simple application of 0.25% desoximetasone cream and its base (twice a day, 12 weeks) in 54 patients with alopecia spots with a clear border, describing that the rate of patients with ≥ 25% hair regeneration was significantly higher in the drug application group, whereas there was no significant difference in complete hair recovery between the two groups.